September 12, 2016Open Access

An Open-Label, Randomized, Parallel, Phase III Trial Evaluating the Efficacy and Safety of Polymeric Micelle-Formulated Paclitaxel Compared to Conventional Cremophor EL-Based Paclitaxel for Recurrent or Metastatic HER2-Negative Breast Cancer

Key Points

Key points are not available for this paper at this time.

Abstract

Compared with standard paclitaxel, Genexol-PM demonstrated non-inferior and even superior clinical efficacy with a manageable safety profile in patients with metastatic breast cancer.

Bookmark

View Full Paper

Cite This Study

Park et al. (Mon,) studied this question.

synapsesocial.com/papers/69d962635e5bcb4e3b835f82 https://doi.org/https://doi.org/10.4143/crt.2016.289

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles2001 · 134 citations
2Synthesis and evaluation of some water-soluble prodrugs and derivatives of taxol with antitumor activity1992 · 250 citations
3Randomized comparison of nab-paclitaxel weekly or every 3 weeks compared to docetaxel every 3 weeks as first-line therapy in patients (pts) with metastatic breast cancer (MBC)2008 · 6 citations
4New Guidelines to Evaluate the Response to Treatment in Solid Tumors2000 · 15,715 citations
5Failure of Higher-Dose Paclitaxel to Improve Outcome in Patients With Metastatic Breast Cancer: Cancer and Leukemia Group B Trial 93422004 · 271 citations

Bookmark

View Full Paper